Clinical Investigator Debarments Speed Up With New Procedures

Washington Drug Letter
The FDA is revamping its debarment and disqualification procedures against clinical investigators by increasing staff and centralizing coordination, and will list investigators against whom it has completed proceedings on its website.

To View This Article:


Buy This Article Now

Add this article to your cart for $10.00